STEM CELL- mit STEM CELL gute Kursgewine erzielen
STEM CELL INNOVATIONS – WKN A0JDMC - mit Stammzellenforschung gute Kursgewinne erzielen
Die Die Analysten vom tradersreport würden eine erste sehr spekulative Longposition in den Aktien der STEM CELL INNOVATIONS mit der WKN A0JDMC bis zu Kursen von 0,003 € eingehen.
Das Thema Stammzellenforschung wurde zum Jahresbeginn 2009 bereits schon einmal angestoßen. Durch die Finanzkrise ist dieses sehr interessante und lukrative Thema etwas aus der Tagespresse verschwunden. Ganz zu Unrecht, da dieses Thema auf der Agenda des neuen US-Präsidenten steht. Neben dem angeschlagenen US-Gesundheitssystems, der Finanzkrise und dem Solarsektor bzw. erneuerbare Energien, steht dieses Thema mit oben auf der Aufgabenliste von Herrn Obama. Nun ist das Spezialgebiet sehr groß und nicht alle Teilbereiche in der Stammzellenforschung werden auch profitabel nutzbar sein. Umso wichtiger wird es sein den richtigen Analyseansatz anzuwenden, um die möglichen Blockbuster-Unternehmen von den lahmen Enten zu trennen.
http://www.be24.at/blog/entry/629436
Optionen
| Boardmail an "brunneta" |
Wertpapier: Stem Cell Innovations |
Optionen
| Boardmail an "bonnie777" |
Wertpapier: Stem Cell Innovations |
Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published by GlobalData on Mar 05, 2012 , 23 pages
§Description Table of Contents
Stem Cell Innovations, Inc. (SCI) is a privately held biotechnology company, based in the US. The company is engaged in the discovery and development of human cell based drugs. Its core technologies concentrate on developing, growing, and manipulating human cells in the laboratory using proprietary technology. The company is into the development of a broad array of human primary cell models, which can be used as powerful research tools to form the basis of therapeutic breakthroughs. SCI has established many human pluripotent stem cell lines fetal gonadal tissue using defined conditions, and the PluriCell lines are established directly onto tissue culture plastic without using feeder layers or conditioned medium. The company also has in vitro hepatocyte screening, kits, compositions, and services for compound toxicity testing, ACTIVTox and PREDICTIVTox in store. SCI is headquartered at Houston in Texas, the US.
Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.
Scope
Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description - A brief description of the company's operations.
Key Employees - A list of the key executives of the company.
Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors - A list of the key competitors of the company.
Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
http://www.boerse-berlin.de/data/publications/Publication_37344.pdf
Allerdings finde ich nach wie vor keine homepage.
http://www.finanznachrichten.de/...m-cell-therapy-use-in-2012-008.htm
26.11.2012 | 20:32
PR Newswire · Mehr Nachrichten von PR Newswire
Dramatic Rise in Stem Cell Therapy Use in 2012
PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ --RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."
Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.
The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.
The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.
The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.
Aastrom Biosciences, Inc.
Advanced Cell Technology
Aldagen, Inc.
AllCells, LLC.
Aruna Biomedical, Inc.
Athersys, Inc.
Bioheart Inc.
BioLife Solutions
BioTime Inc./Embryome Sciences, Inc.
Brainstorm Cell Therapeutics
Case Western Reserve University
CellCyte Genetics Corp.
Celgene Corporation
Celtigen Therapeutics
Cord Blood America, Inc. (CBAI.OB)
Core Dynamics Ltd.
Cytori Therapeutics, Inc.
Gamida Cell Ltd.
Garnet BioTherapeutics, Inc.
Histogen Inc
INCELL Corporation LLC
International Stem Cell Corporation
Lifenet Health
Lonza Group Ltd.
§
Medistem Inc.
Mesoblast Limited
MultiCell Technologies [MCET]
Neostem, Inc.
Neuralstem
Opexa Therapeutics, Inc.
Osiris Therapeutics, Inc.
Parcell Labs
Pathfinder Cell Therapy
Pervasis Therapeutics, Inc.
Pluristem Therapeutics, Inc.
Prochon Biotech, Ltd.
Progenitor Cell Therapy, LLC
Stem Cell Innovations
Stem Cell Therapeutics (SCTPF)
StemCells Inc.
TiGenix NV
Tissue Genesis, Inc.
TxCell
Vet-Stem, Inc.
ViaCyte
WuXi AppTec
In addition to the company and product overviews, Robin Young, president of RRY Publications and the organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry.
8th Annual New York Stem Cell Summit Facts at a Glance
What:
§
Largest Gathering of Stem Cell Company Executives, Scientists, Investors, and Physicians
When:
§
February 19, 2013
Where:
Bridgewaters
§
11 Fulton Street
§
New York City
Who:
§
The Stem Cell Summit is organized by RRY Publications LLC
Admission:
§
$950 through November 2012
§
$1,500 Registration (February 1, 2013 - February 19, 2013 and onsite)
Information:
§
For more information on presentation or sponsorship opportunities, call Bharathi Kavalipati at
§
610-260-6462 or send an email to bharathi@ryortho.com
§
Additional information, including attendee registration details, is available at www.stemcellsummit.com
Contacts:
§
Suzanne Kirchner
§
RRY Publications LLC
501-251-1797
§
skirchner@ryortho.com
Optionen
| Boardmail an "ridgeback" |
Wertpapier: Stem Cell Innovations |
Gehandelt wird schon lange nichts mehr, aber ganz weg sind sie scheinbar auch nicht, denn sonst würde diese Position ja aus meinem Depot gelöscht werden.
Ich habe keine Ahnung was hier abgeht !
Aus welchem Grund findet seit längerem kein Handel mehr statt, obwohl die Aktie noch aktiv ist?
